23andMe, Inc. Company Profile

05:12 EST 21st November 2017 | BioPortfolio

23andMe, Inc. is a leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company's Personal Genome Service(TM) enables individuals to gain deeper insights into their ancestry and inherited traits. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. Its Series A investors include Genentech, Inc., Google Inc. and New Enterprise Associates. More information is available at

News Articles [33 Associated News Articles listed on BioPortfolio]

"It's Really Important Not To Be Afraid Of Conflict," Says 23andMe Cofounder

23andMe has had a rocky road with the FDA. But now the company seems to have figured out how to work with federal regulators.

23andMe raises $250m in financing, research points towards its future

23andMe made two announcements on the same day that point towards the future of its business: it revealed it had raised $250 million in financing and released details from a long-running study into Pa...

Michael J. Fox Foundation, 23andMe collaborate

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe announced a collaboration to build a large, diverse cohort of both patients and control volunteers who have consented to...

23andMe to probe role of genetics on depression and bipolar disorders

23andMe has launched a study to understand the role of genetics in some of the major depressive and bipolar disorders.

23andMe’s Second Act Sits Squarely in Drug Research and Development

(Tech Crunch) – 23andMe is best known for its $199 at-home spit-tube DNA test, but the consumer genetics company has been making strides in the last few years to get into drug development and re...

STAT Plus: Michael J. Fox Foundation partners with 23andMe for precision medicine project on Parkinson’s

A $4 million study by the Michael J. Fox Foundation for Parkinson’s Research and 23andMe aims to see if a precision-medicine approach might work.

23andMe Raises $250M For Consumer Disease-Risk Tests, Drug R&D

Once barred from giving consumers disease-related information about their DNA, 23andMe recently received approval to market such genetic tests directly to consumers—and it now has reeled in a bo...

Genetics company 23andMe raises $250mm in late-stage growth financing

23andMe Inc. (consumer genetics and research) raised $250mm in what appears to be its Series F growth financing round led by new investor Sequoia Capital (adds board seat). New investors Euclidean Ca...

Drugs and Medications [0 Results]


PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

23andMe wades further into drug discovery.

23andMe Paves the Way for Direct-to-Consumer Genetic Health Risk Tests of Limited Clinical Utility.

Genetic Basis of Chronotype in Humans: Insights From Three Landmark GWAS.

Chronotype, or diurnal preference, refers to behavioral manifestations of the endogenous circadian system that governs preferred timing of sleep and wake. As variations in circadian timing and system ...

Phenome-wide association study using research participants' self-reported data provides insight into the Th17 and IL-17 pathway.

A phenome-wide association study of variants in genes in the Th17 and IL-17 pathway was performed using self-reported phenotypes and genetic data from 521,000 research participants of 23andMe. Results...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

MyGeneRank: A Digital Platform for Next-Generation Genetic Studies

Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developi...

Companies [3 Associated Companies listed on BioPortfolio]

23andMe, Inc.

23andMe, Inc. is a leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The co...

23andMe Inc.


Cureatr is the nation’s fastest growing mobile care coordination solution for healthcare providers. By combining HIPAA-secure text messaging with workflow navigation tools to...

More Information about "23andMe, Inc." on BioPortfolio

We have published hundreds of 23andMe, Inc. news stories on BioPortfolio along with dozens of 23andMe, Inc. Clinical Trials and PubMed Articles about 23andMe, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 23andMe, Inc. Companies in our database. You can also find out about relevant 23andMe, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record